An exploratory analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) randomized double-blind, placebo-controlled trial found that patients receiving interleukin-1β (IL-1β) inhibitors ...
Aug 4, 2020
0
5
(HealthDay)—Inhibition of interleukin-1β (IL-1β) with canakinumab is associated with reduced incident anemia as well as improved hemoglobin levels among patients with baseline anemia, according to research published online ...
Mar 24, 2020
0
2
Inflammation, long considered a dangerous contributor to atherosclerosis, actually plays an important role in preventing heart attacks and strokes, new research from the University of Virginia School of Medicine reveals.
Sep 19, 2018
0
252
